Good News: Human trial of COVAXIN, India’s first Covid-19 vaccine begins at AIIMS-Patna

New Delhi: Taking the lead in fight against Coronavirus, AIIMS Patna has begun the human trial of COVAXIN, India’s first indigenous Covid-19 vaccine.

Covaxin has been jointly developed by Bharat Biotech International Limited (BBIL) and National Institute of Virology, Pune in collaboration with the Indian Council of Medical Research (ICMR).

AIIMS-Patna has started testing the candidate vaccine on 10 volunteers picked by the hospital authority for the trial, according to a report by All India Radio (AIR). The first dose of the vaccine has been administered to selected people while second dose will be given after 14 days.

COVAXIN to be tested on 1,000 people in 2 phases

Several people offered to take part in the trial, but only 10 people were selected for the process. AIIMS – Patna is one of the 12 medical institutes in the country to have been shortlisted by ICMR for conducting the human trial of the indigenous vaccine.

COVAXIN will be tested on more than 1,000 people in two phases, say reports.

Coronavirus gathers pace in Bihar

With spurt in Coronavirus cases, experts fear that Bihar may emerge as next Corona hotspot in the country.

Fresh Covid-19 cases have been breaching the 1,000-mark in Bihar for the last four days, with infection rate rising continuously. Total cases recorded so far in the state is likely to cross the 20,000-mark today.